Skip to main content

Table 5 Expression of ER, PR, HER 2 and EGFR by biomarkers whose expression significantly differed between subtypes

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

  ER P PR P HER2 P EGFR P
Biomarkers Positive
(%)
Negative
(%)
Positive (%) Negative (%) Positive
(%)
Negative
(%)
Positive
(%)
Negative
(%)
PTEN 0.76    0.10    <0.01    0.80
Reduced 163 (50.3) 71 (52.2) 134 (47.7) 100 (55.9) 34 (34.3) 200 (55.4) 39 (52.7) 195 (50.9)
Normal 161 (49.7) 65 (47.8) 147 (52.3) 79 (44.1) 65 (65.7) 161 (44.6) 35 (47.3) 188 (49.1)
Bcl- 2 <0.01    <0.01    <0.01    <0.01
Positive 268 (82.0) 35 (25.7) 238 (83.2) 65 (36.7) 34 (34.7) 269 (73.7) 20 (27.4) 279 (72.5)
Negative 59 (18.0) 101 (74.3) 48 (16.8) 112 (63.3) 64 (65.3) 96 (26.3) 53 (73.4) 106 (27.5)
c -Kit    <0.01    <0.01    1.00    <0.01
Positive 15 (4.5) 18 (13.2) 11 (3.8) 22 (12.3) 7 (7.1) 26 (7.1) 16 (21.6) 16 (4.1)
Negative 315 (95.5) 118 (86.8) 276 (96.2) 157 (87.7) 92 (92.9) 341 (92.9) 58 (78.4) 371 (95.9)
c- Met 0.42    0.16    <0.01    0.046
Positive 229 (71.3) 99 (75.6) 194 (70.0) 134 (76.6) 81 (84.4) 247 (69.4) 60 (82.2) 267 (70.8)
Negative 92 (28.7) 32 (24.4) 83 (30.0) 41 (23.4) 15 (15.6) 109 (30.6) 13 (17.8) 110 (29.2)
Survivin    0.03    0.06    <0.01    0.24
Positive 263 (80.0) 120 (88.2) 228 (79.7) 155 (86.6) 90 (91.8) 293 (79.8) 64 (87.7) 314 (81.1)
Negative 66 (20.0) 16 (11.8) 58 (20.3) 24 (13.4) 8 (8.2) 74 (20.2) 9 (12.3) 73 (18.9)
  1. Fisher's exact probability test was used for statistical analysis.
  2. ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor type 2, EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.